HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine development
- 6 June 2008
- Vol. 26 (24) , 3026-3035
- https://doi.org/10.1016/j.vaccine.2007.12.026
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusionMolecular Membrane Biology, 2008
- Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazideBiochemical and Biophysical Research Communications, 2007
- Sphingomyelinase Restricts the Lateral Diffusion of CD4 and Inhibits Human Immunodeficiency Virus FusionJournal of Virology, 2007
- Exposure of the Membrane-Proximal External Region of HIV-1 gp41 in the Course of HIV-1 Envelope Glycoprotein-Mediated FusionBiochemistry, 2007
- Fusion-Induced Apoptosis Contributes to Thymocyte Depletion by a Pathogenic Human Immunodeficiency Virus Type 1 Envelope in the Human ThymusJournal of Virology, 2006
- Fenretinide inhibits HIV infection by promoting viral endocytosisAntiviral Research, 2006
- Conformational Changes in HIV-1 gp41 in the Course of HIV-1 Envelope Glycoprotein-Mediated Fusion and InactivationBiochemistry, 2005
- Mechanisms of apoptosis induction by the HIV-1 envelopeCell Death & Differentiation, 2005
- Role of Cholesterol in Human Immunodeficiency Virus Type 1 Envelope Protein-Mediated Fusion with Host CellsJournal of Virology, 2002
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993